Pegylated OXM variants
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
1. A conjugate consisting of an oxyntomodulin, a polyethylene glycol polymer (PEG polymer) and 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), wherein said PEG polymer is attached to the amino terminus of said oxyntomodulin or to a lysine residue on position number twelve (Lys 12 ) of said oxyntomodulin, via Fmoc or FMS.
2. The conjugate of claim 1 , wherein said oxyntomodulin consists of the amino acid sequence set forth in SEQ ID NO: 1.
3. The conjugate of claim 1 , wherein said PEG polymer is a PEG polymer with a sulfhydryl moiety.
4. The conjugate of claim 1 , wherein said PEG polymer is PEG30.
5. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutical acceptable carrier.
6. A method of inducing glucose tolerance in a subject in need thereof, or increasing insulin sensitivity in a subject in need thereof, or inducing glycemic control in a subject in need thereof, or reducing insulin resistance in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 5 .
7. A method of reducing food intake in a subject in need thereof, or reducing body weight in a subject in need thereof, or for increasing energy expenditure in a subject in need thereof, or improving the cholesterol levels in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 5 .